Form 4: MAIA Biotechnology CEO Boosts Stake with Significant Share Purchases

MAIA Biotechnology's CEO, Vlad Vitoc, has significantly increased his direct ownership in the company through two recent open market purchases.

Summary

• Vlad Vitoc, Chief Executive Officer, Director, and 10% Owner of MAIA Biotechnology, Inc. (MAIA), reported two direct purchases of common stock.
• On November 26, 2025, Mr. Vitoc purchased 22,000 shares at a weighted average price of $1.0463 per share, ranging from $1.0145 to $1.0587.
• On November 28, 2025, Mr. Vitoc purchased an additional 50,000 shares at a weighted average price of $1.1366 per share, ranging from $1.1283 to $1.1416.
• Following these transactions, Mr. Vitoc directly owns 881,421 shares of MAIA Biotechnology Common Stock.
• An additional 210,000 shares are beneficially owned indirectly by Mr. Vitoc's spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to significant open market purchases by the CEO, Director, and 10% owner, indicating strong insider confidence in the company's future.

Positives

• The Chief Executive Officer, a Director, and a 10% owner, Vlad Vitoc, made substantial open market purchases of the company's common stock, signaling strong confidence in the company's future prospects.
• The total direct shares purchased amount to 72,000, representing a significant personal investment by a key insider.
• The purchases were made at varying price points, indicating a belief in the stock's value across a range.

Risks

• The price ranges for the purchases ($1.0145 to $1.0587 and $1.1283 to $1.1416) indicate some volatility in the stock price around the transaction dates.
• Insider buying, while generally positive, does not guarantee future stock performance or company success.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance, but the significant insider purchases by the CEO implicitly suggest a positive outlook from management regarding the company's future performance and valuation.

Management Comments

• The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Industry Context

Insider buying, particularly by a CEO, in the biotechnology sector can be a strong indicator of management's belief in upcoming clinical milestones, regulatory approvals, or commercialization success, especially given the inherent risks and long development cycles in the industry.

Related Party Transactions

• 210,000 shares are beneficially owned indirectly by Mr. Vitoc's spouse. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Stakeholder Impact

• Shareholders may view these insider purchases as a positive signal, potentially increasing investor confidence and demand for the stock.
• Employees might interpret the CEO's increased stake as a sign of stability and belief in the company's long-term vision.

Key Dates

Recommendation

The Chief Executive Officer, who is also a Director and a 10% owner, has made substantial open market purchases of MAIA Biotechnology stock. This significant insider buying, totaling 72,000 shares, is a powerful indicator of management's conviction in the company's intrinsic value and future growth trajectory. Such discretionary purchases, not made under a 10b5-1 plan, suggest a strong belief in the current valuation and upcoming catalysts. This action by a key insider typically signals a 'strong buy' to seasoned investors, as it aligns management's interests directly with shareholder value creation.

Keywords

MAIA Biotechnology, MAIA, Vlad Vitoc, Insider Buying, CEO Purchase, Form 4, Stock Purchase, Biotechnology, Director, 10% Owner